TY  - CONF

T1  - Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA)

JO  - JOURNAL OF CLINICAL ONCOLOGY

PY  - 2012/05/20

AU  - Sartor AO

AU  - Heinrich D

AU  - O'Sullivan JM

AU  - Fossa SD

AU  - Chodacki A

AU  - Wiechno PJ

AU  - Logue JP

AU  - Seke M

AU  - Widmark A

AU  - Johannessen DC

AU  - Nilsson S et al

ED  - 

VL  - 30

IS  - 15

Y2  - 2025/10/10

ER  -